Rapid emergence of protease inhibitor resistance in hepatitis C virus. - Test2 - elhamkhani - TriplyDB

Rapid emergence of protease inhibitor resistance in hepatitis C virus.

Rapid emergence of protease inhibitor resistance in hepatitis C virus.

http://www.wikidata.org/entity/Q34551913

about

Targeted DNA mutagenesis for the cure of chronic viral infections Hepatitis C virus protease inhibitor-resistance mutations: our experience and review Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistance Hepatitis C genotype 4: The past, present, and future Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection HCV Kinetic Models and Their Implications in Drug Development Viral kinetic modeling: state of the art Evolutionary rescue: linking theory for conservation and medicine Modelling hepatitis C therapy--predicting effects of treatment Future classes of hepatitis C virus therapeutic agents Predicting resistance mutations using protein design algorithms The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors The FDA-approved drug sofosbuvir inhibits Zika virus infection A novel small molecule inhibitor of hepatitis C virus entry Mathematical model of viral kinetics in vitro estimates the number of E2-CD81 complexes necessary for hepatitis C virus entry Cellular growth kinetics distinguish a cyclophilin inhibitor from an HSP90 inhibitor as a selective inhibitor of hepatitis C virus Probing of exosites leads to novel inhibitor scaffolds of HCV NS3/4A proteinase HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors Spontaneous clearance of viral infections by mesoscopic fluctuations Deep sequencing analysis of HCV NS3 resistance-associated variants and mutation linkage in liver transplant recipients A novel compound from the mushroom Cryptoporus volvatus inhibits porcine reproductive and respiratory syndrome virus (PRRSV) in vitro A quantitative high-resolution genetic profile rapidly identifies sequence determinants of hepatitis C viral fitness and drug sensitivity Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents Intact dendritic cell pathogen-recognition receptor functions associate with chronic hepatitis C treatment-induced viral clearance A new stochastic model for subgenomic hepatitis C virus replication considers drug resistant mutants A hepatitis C virus infection model with time-varying drug effectiveness: solution and analysis Modeling viral evolutionary dynamics after telaprevir-based treatment Rational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus Infection Analysis of Dengue Virus Genetic Diversity during Human and Mosquito Infection Reveals Genetic Constraints Multiple Introduction and Naturally Occuring Drug Resistance of HCV among HIV-Infected Intravenous Drug Users in Yunnan: An Origin of China's HIV/HCV Epidemics Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials Natural HCV variants with increased replicative fitness due to NS3 helicase mutations in the C-terminal helix α18 Treatment of hepatitis C with an interferon-based lead-in phase: a perspective from mathematical modelling Replication vesicles are load- and choke-points in the hepatitis C virus lifecycle.The hepatitis C virus NS5A inhibitor daclatasvir has a dual mode of action and leads to a new virus half-life estimate Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy.Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action.A new model to produce infectious hepatitis C virus without the replication requirement.Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patients A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection.

P2860

Q24620150-AA5A2872-6A5B-4A18-8D26-E65B21FAC063 Q24628717-D7FB7E3E-10A6-4044-B988-B26982E07BFB Q26740219-4112841E-D4F3-4DB5-9F5F-4B8495D14681 Q26775815-A615708E-5C85-46B7-AEAF-712977176910 Q26775825-A58D3E2E-3D94-4F0E-8D56-AB2F05A0ED8E Q26801602-D7DB5A77-C073-44C0-91F6-2E8AE5127FCA Q26824655-324EFE46-A436-49D3-955B-D2A589137FAF Q26862297-9056BFD4-D36D-4507-A397-456858BB1BFB Q26864673-0E5DEA48-B682-4BFB-8FED-F4F0390A9FB2 Q27009321-43CB7088-A7C0-4921-B386-C2847C6B906F Q27663576-9C699C92-9729-4662-B10A-7F7D12C42663 Q27671640-A86F4D48-4C89-42AE-AEB9-15AF331D67FE Q27924226-78AA5A2E-BC1B-44B1-BA22-AE20D7F632AE Q28475468-7B289AE6-CC8F-4EC8-89D6-1A94DE322036 Q28478310-6E613526-D34F-4E89-9B31-E83B1FB076E0 Q28480556-CE2976D8-4C67-41B1-B0B1-32FA5BDD989A Q28480947-AFE854B8-6497-4F60-8409-16332C972A46 Q28481038-01ABBD0D-4A15-4DBB-95BD-FC4EE0E8D239 Q28484092-E6E6B124-2F01-45E6-ABC0-B9A94696D4BC Q28534965-BF9BE9EA-90D1-47C0-847B-5A39ECEB8E2C Q28535225-97DC1301-4A23-4C93-8225-46191A0323D7 Q28537708-DDB92651-9B80-4457-8D9C-21F4C0869920 Q28538891-751A8A5C-6F72-4961-A2F9-2F7E191703A9 Q28540848-D809E2D8-EB92-4F9E-B4F8-DD49EB42F261 Q28541048-DC97F874-8D76-44C7-8DEB-159C12710C53 Q28541682-80B93113-3C2F-4BDE-8334-DC88251C205B Q28542375-1913A5BB-72CA-4017-A78B-19EA67FAD822 Q28545971-58CF8D9C-73C6-4D0A-A580-8F4A2970FBA7 Q28547668-DC5000C5-7D3F-455B-A395-D8B9486CA686 Q28550924-E1FA8793-25A9-459C-8090-4FADD8BE0711 Q28730617-88454386-3E6A-482E-BBAE-81617B30FDEA Q30383665-2CC0D045-FA0B-4F33-A574-993D60D7E443 Q30583856-528BD36B-F847-4933-8346-FC49C6C08F30 Q31129723-4C500156-DC1F-499E-9713-DB2D14153DDC Q33794371-8FEBC351-BDE3-4351-9013-DFB9CC8E49BA Q33815550-69D5C8D6-AF86-4F2C-BA13-2B7E36303EFD Q33878202-4369155A-CD27-4B17-8CA1-40B678C8DE18 Q33886707-F3433FFD-9D53-481E-A68C-80A08C584F8A Q34057340-DE9DB03F-C3C6-4376-B645-18CF85E4DE99 Q34126254-C286841E-D149-45EA-A9DB-FF2CE4ED7AC3

P2860

Rapid emergence of protease inhibitor resistance in hepatitis C virus.

http://www.wikidata.org/entity/Q34551913

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Rapid emergence of protease inhibitor resistance in hepatitis C virus.

@ast

Rapid emergence of protease inhibitor resistance in hepatitis C virus.

@en

Rapid emergence of protease inhibitor resistance in hepatitis C virus.

@nl

type

label

Rapid emergence of protease inhibitor resistance in hepatitis C virus.

@ast

Rapid emergence of protease inhibitor resistance in hepatitis C virus.

@en

Rapid emergence of protease inhibitor resistance in hepatitis C virus.

@nl

prefLabel

Rapid emergence of protease inhibitor resistance in hepatitis C virus.

@ast

Rapid emergence of protease inhibitor resistance in hepatitis C virus.

@en

Rapid emergence of protease inhibitor resistance in hepatitis C virus.

@nl

P1433

Q34551913-3135B93C-5D3B-4EF9-9D58-3A5207788DA4

P1476

Q34551913-F40AC1C3-28ED-4B6B-97E7-8BFA0C3B4EC3

P2093

Q34551913-0239FC20-0330-4B06-A53E-893AA5A0AA24

Q34551913-A7F414F9-A30D-4072-9507-BAF7122C421B

P2860

Q34551913-08FC2244-954C-4079-BA63-33510924DC03

Q34551913-0D346CB1-747E-488C-BB16-0E9EE6E3E8C7

Q34551913-0EDBA9BD-AAE3-419C-8984-213F4DAACFCD

Q34551913-171F6A96-7722-4611-96A7-EF5521B772F4

Q34551913-17DCDD5E-6F80-48E9-B9F4-20FB43E58770

Q34551913-186C6F32-08D9-4041-86D3-561409B4BB74

Q34551913-1BC0D5D2-5DF5-42BE-94D8-8CBF950A95FD

Q34551913-1EEC60B1-5E6E-4740-805F-EFFCAADEFE99

Q34551913-27D811DD-67E4-41DD-946B-E7343237D67E

Q34551913-2ABF8728-E321-4063-9CBB-77F5DB9916D8

P304

Q34551913-A3B0CC9C-9142-49B9-8CC9-5291A348E5F1

P31

Q34551913-F5C50004-465F-4F63-834C-0893F39FEF33

P356

Q34551913-25193925-8BC2-4DBF-A7D2-7ED82DCF6F5B

P407

Q34551913-7A90CAB5-03F2-4833-9874-38E7F368D636

P433

Q34551913-2C9AED60-73DD-471F-819D-E8ADD18767E5

P478

Q34551913-F021F5C3-ED3E-4805-959F-78C6E4DAE1BD

P50

Q34551913-EEF3579D-58D1-4869-A361-BEDC31D31B6B

Q34551913-F6490EB5-ED08-4234-A422-F6EA9ED5ABC9

P577

Q34551913-96DD3790-5E8F-486A-81D0-D4AEF974F58E

P5875

Q34551913-F6CBB2F7-D923-49F9-A9A6-EAF3DF69C3E8

P698

Q34551913-0D79BD89-88B6-4A62-9C08-14FCAE784620

P932

Q34551913-E85FFBC0-F8B3-46A3-BE34-A55F75143D03

P356

SCITRANSLMED.3000544

P1433

Science Translational Medicine

P1476

Rapid emergence of protease inhibitor resistance in hepatitis C virus.

@en

P2093

Harel Dahari

http://www.w3.org/2001/XMLSchema#string

Libin Rong

http://www.w3.org/2001/XMLSchema#string

P2860

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells.

VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells

Percentage of Hepatitis C Virus-Infected Hepatocytes Is a Better Predictor of Response Than Serum Viremia Levels

Phenotypic Characterization of Resistant Val36 Variants of Hepatitis C Virus NS3-4A Serine Protease

The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors

Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796

Effect of Ribavirin on the Mutation Rate and Spectrum of Hepatitis C Virus In Vivo

P304

30ra32

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCITRANSLMED.3000544

http://www.w3.org/2001/XMLSchema#string

P407

P433

30

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Alan S. Perelson

P577

2010-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44575786

http://www.w3.org/2001/XMLSchema#string

P698

20445200

http://www.w3.org/2001/XMLSchema#string

P932

3033690

http://www.w3.org/2001/XMLSchema#string